Soiken Holdings Inc.
Notice of the conclusion of a joint research framework agreement for new functional materials with the China-based Sichuan Colun Pharmaceutical Group
Entered into a joint research framework agreement with the China-based Sichuan Colun Pharmaceutical Group. Aiming to research, develop, and commercialize functional materials in the Japanese market; domestic clinical studies and functional assessments to be conducted by Soiken Holdings, with Sino-Japanese coordination by Sennitte BioTechnology Co., Ltd., and development foundations provided by Colun Yongnian. Cross-border e-commerce and Chinese market expansion are also envisioned. Impact on current-period performance is not yet determined.
Key Figures
- Name of new functional material is not disclosed
- Market capitalization of Sichuan Colun Pharmaceutical Group is unknown
- FY2025 net sales are unknown
AI要約
Overview of the business alliance
This agreement forms a framework whereby Soiken Holdings and its group company with Sichuan Colun Pharmaceutical Group's group companies will jointly promote research, development, evaluation, and commercialization of new functional materials starting from the Japanese market. Soiken Holdings will undertake clinical studies and functional evaluations in Japan domestic, Sennitte will handle cross-border coordination between Japan and China, and Colun Yongnian will provide the development foundation.
Outlook and impact
We will advance scientific evidence through clinical studies and functional evaluations in the Japanese market, considering expansion to products such as foods with functional claims. Subsequently, we will explore sales expansion in the Chinese market including cross-border e-commerce, aiming to build a bi-directional Japan-China business model. Note that the impact of this agreement on earnings is under thorough review and will be disclosed as progress occurs.
Soiken Holdings Inc.
Company overview · Stock price · Financial data · All IR
